Effects of denosumab on bone mineral density around proximal femoral prosthesis after total hip replacement in postmenopausal osteoporotic patients.
10.12200/j.issn.1003-0034.2023.11.007
- Author:
Wei-Hong NING
1
;
Guo-Zhu XU
1
;
Jian-Wei WANG
1
Author Information
1. Department of Orthopaedics, Traditional Chinese Medical Hospital of Changxing, Huzhou 313100, Zhejiang, China.
- Publication Type:Journal Article
- Keywords:
Denosumab;
Postmenopausal osteoporosis;
Total hip arthroplasty(THA)
- MeSH:
Humans;
Arthroplasty, Replacement, Hip;
Bone Density;
Denosumab/therapeutic use*;
Retrospective Studies;
Postmenopause;
Absorptiometry, Photon;
Bone Remodeling;
Follow-Up Studies;
Hip Prosthesis
- From:
China Journal of Orthopaedics and Traumatology
2023;36(11):1041-1045
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the effect of denosumab on bone mineral density around proximal femoral prosthesis after total hip arthroplasty(THA) in the postmenopausal osteoporotic patients.
METHODS:Fifty-four consecutive patients underwent unilateral primary THA were included in this retrospective study. Twenty-five patients received denosumab for osteoporosis as the treatment group, and the twenty-nine without denosumab were the control group. At 1 week, 3month, 6 months, and 12 months after THA, bone turnover markers and proximal femoral periprosthetic bone mineral density (BMD) were measured.
RESULTS:At 3, 6 and 12 months after operation, the level of TRACP-5b in the control group was significantly higher than that in the treatment group (P<0.05);the level of bone-specific alkaline phosphatase (BALP) between two groups showed significant difference in 12 months after operation (control group was higher than treatment group, P<0.05). The BMD of Gruen 1 and Gruen 7 decreased at 3, 6 and 12 months after operation compared with 1 week after operation. Comparing the treatment group and the control group, the differences of the the decrease of BMD in Gruen 1 and Gruen 7 were no significant at 3 months after surgery. In Gruen 1, Gruen 7 at 6 months after operation and Gruen 1, Gruen 7 at 12 months after operation, the decrease of BMD in the control group was significantly higher than that in the treatment group(P<0.05). It is suggested that desudumab could inhibit the loss of BMD after 6 months, and continuously show a protective effect on bone mass at 12 months after operation.
CONCLUSION:After THA in postmenopausal patients with osteoporotic femoral neck fracture, Desuzumab can reduce the loss of BMD around the proximal femoral prosthesis and effectively inhibit bone resorption.
